Rotimi Mesubi

[Rotimi Mesubi @RMesubi]

@temidayo @LondonMarathon @WMMajors @nycmarathon Way to go! You are an inspiration!

[Rotimi Mesubi @RMesubi]

@VirginiaSHahnMD @JR_Goldenberg Congratulations

[Rotimi Mesubi @RMesubi]

@UREssien You did not disappoint with the bow- ties!!!

[Rotimi Mesubi @RMesubi]

@GbengaOgedegbe @AHAScience @nyulangone @pophealthNYC @nyugsom_iehe @nyugrossman @American_Heart Congratulations!

[Rotimi Mesubi @RMesubi]

Congratulations to @Oscarreyesgaido, winner of this year’s AHA Katz Basic Science Research award and to our indefatigable mentor Dr. Mark Anderson. Looking forward to more Katz and Marcus AHA winners from this pedigree! @priyaumapathi @KlitosKon @betsy_luczak

[PBS News @NewsHour]

There’s worry about what the Supreme Court’s ruling on affirmative action could mean for the pipeline of who eventually provides health care in the U.S.

For more on these concerns, @IAmAmnaNawaz spoke to @UREssien. https://t.co/x2wbLMyl6O

[Rotimi Mesubi @RMesubi]

@CardioNerdsJC Negative studies are still useful for providing information and prevents others from making the same assumptions

[Rotimi Mesubi @RMesubi]

@yreddyhf @CardioNerdsJC Still begs the question - what do you do in HFpEF patients with symptomatic bradycardia/SND

[Rotimi Mesubi @RMesubi]

@RyanTedfordMD @CardioNerdsJC This brings up another issue - HFpEF is a heterogeneous disease, yet we keep treating it as one disease. Maybe sub-populations of HFpEF patients stand to benefit or suffer harm.

[Rotimi Mesubi @RMesubi]

@CardioNerdsJC The incidence of adverse outcomes seems relatively high in this study. #CardsJC

[Rotimi Mesubi @RMesubi]

@EJSMD @rdschaller In this study, it will also have been difficult to determine if symptoms were due to SND vs HFpEF. #CardsJC

[Rotimi Mesubi @RMesubi]

@CardioNerdsJC The authors suggest this was done to as a measure of sub maximal exercise performance more representative of ADLs. #CardsJC

[Rotimi Mesubi @RMesubi]

@OscarIReyes1 @NkashamaLubika @DrDiastole

[Rotimi Mesubi @RMesubi]

An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor | Science Translational Medicine https://t.co/f3BJWmoPCo

[Utibe R. Essien, MD MPH @UREssien]

1/ 🧵 NEW Paper.

In @JAMACardio we asked: are there racial/ethnic disparities in treatment & outcomes in the Get With the Guidelines - AFIB Registry.

Short answer: YES.

Here’s what we found, what it means, and what we can do to achieve #Pharmacoequity.

https://t.co/O4FsVTxnmJ

[Rotimi Mesubi @RMesubi]

@LarryRJacksonII @gdelriopertuz @CardioNerdsJC That's a study waiting to be done! #CardsJC

[Rotimi Mesubi @RMesubi]

Based on the data in this paper, there is not enough evidence for routine screening, especially with the Kardia device at a clinic visit to a primary care visit. #CardsJC

[Rotimi Mesubi @RMesubi]

In addition to cost issues with continuous monitoring of ECG, there is the administrative and clinical burden of the data overload. #CardsJC

[Rotimi Mesubi @RMesubi]

@KTamirisaMD @HafizaKMD @RajendraPShahMD @CardioNerdsJC I think the brings up two issues -
1) Access to care
2) Quality of care, when there is access. Presumably a good quality physical exam (for pulse) vs ECG vs a device like Kardia will give approximate results (don't have any data on this!)

[Rotimi Mesubi @RMesubi]

The average BMI in this study was ~ 28. This is certainly much lower than I see in my practice and may have also affected the outcomes. Obesity is a known risk factor for AF. I may send my patients to MA for weight loss therapy! #CardsJC